[1]石惠薇 热娜提·肉孜 刘硕霖 吴娜琼.高脂蛋白a血症的相关治疗进展[J].心血管病学进展,2021,(4):297-301.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
　SHI Huiwei,Rinat·Rozi,LIU Shuolin,et al.Lipoprotein(a)-lowering Therapy[J].Advances in Cardiovascular Diseases,2021,(4):297-301.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
点击复制

高脂蛋白a血症的相关治疗进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年4期
页码:
297-301
栏目:
综述
出版日期:
2021-04-25

文章信息/Info

Title:
Lipoprotein(a)-lowering Therapy
作者:
石惠薇 热娜提·肉孜 刘硕霖 吴娜琼
(中国医学科学院阜外医院 国家心血管病中心 内分泌与心血管代谢中心,北京 100037)
Author(s):
SHI Huiwei; Rinat·Rozi; LIU Shuolin; WU Naqiong
(Endocrinology&Cardiometabolic Center,State Key Laboratory of Cardiovascular Disease,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)
关键词:
脂蛋白(a); 米泊美生; 前蛋白转化酶枯草溶菌素9抑制剂; 脂蛋白分离术; 反义寡核苷酸
Keywords:
Lipoprotein(a)MipomersenProprotein convertase subtilisin kexin type 9 inhibitorsLipoprotein apheresisAntisense oligonucleotides
DOI:
10.16806/j.cnki.issn.1004-3934.2021.04.003
摘要:
有研究证实血浆脂蛋白(a)水平是动脉粥样硬化性心血管疾病和钙化性主动脉瓣疾病的独立危险因素。指南建议Lp(a)>50 mg/dL(100~125 nmol/L)是风险显著增加的阈值。降低Lp(a)水平是降低动脉粥样硬化性心血管疾病或钙化性主动脉瓣疾病风险并改善预后的重要策略。然而让人失望的是，传统的降脂疗法如他汀不能显著降低Lp(a)水平。烟酸虽然可有效降低Lp(a)，但却没有心血管获益。对于Lp(a)水平极高或严重心血管疾病的患者，脂蛋白分离术是一个可选择的方法。新型的治疗手段如米泊美生、洛美他派、前蛋白转化酶枯草溶菌素9（PCSK9）型抑制剂等可降低Lp(a)的水平，同时，有证据表明，正在研发中的载脂蛋白A反义寡核苷酸可有效大幅降低血浆脂蛋白(a)的水平。现针对传统降脂疗法与新型疗法对Lp(a)水平的影响做一综述。
Abstract:
Recent studies have provided substantial evidences that elevated plasma lipoprotein(a) [Lp(a)] level played a causal,independent role in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Lp(a) >50 mg/dL (100 ~125 nmol/L) was recommended as a cutoff value of remarkable risk. It should be an important strategy to reduce the risk and to improve the prognosis of ASCVD or CAVD by decreasing the level of Lp(a). However,it was so disappointing that traditional lipid-lowering therapies including statins,which could not decrease,but increase the level of Lp(a).Although niacins had been shown to effectively lower Lp(a),they had no significant cardiovascular disease benefits. For patients with extremely high Lp(a) levels or severe cardiovascular disease,lipoprotein apheresis may be an optimal choice. Emerging therapeutic interventions,such as mipomersen,proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors,the antisense oligonucleotides of apo(a) could reduce the level of Lp(a). Here we performed a review to assess the effects on the level of Lp(a) of both existing approaches and compounds under development.

参考文献/References:


[1] Tsimikas S. A test in context: lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6):692-711.

[2] Choi SH,Chae A,Miller E,et al. Relationship between biomarkers of oxidized low-density lipoprotein,statin therapy,quantitative coronary angiography,and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study[J]. J Am Coll Cardiol,2008,52(1):24-32.

[3] Fraley AE,Schwartz GG,Olsson AG,et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors,inflammatory biomarkers,and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial[J]. J Am Coll Cardiol,2009,53(23): 2186-2196.

[4] Moura LM,Ramos SF,Zamorano JL,et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis[J]. J Am Coll Cardiol,2007,49(5):554-561.

[5] Rossebo AB,Pedersen TR,Boman K,et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis[J]. N Engl J Med,2008,359(13):1343-1356.

[6] Yoshida H,Shoda T,Yanai H,et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia[J]. Atherosclerosis,2013,226(1):161-164.

[7] Chan KL,Teo K,Dumesnil JG,et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial[J]. Circulation,2010,121(2): 306-314.

[8] Ky B,Burke A,Tsimikas S,et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans[J]. J Am Coll Cardiol,2008,51(17):1653-1662.

[9] AIM-HIGH Investigators,Boden WE,Probstfield JL,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med,2011,365(24):2255-2267.

[10] Goldberg RB, Bittner VA, Dunbar RL ,et al. Effects of extended-release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM-HIGH[J]. Am J Med,2016,129(7):e13-22.

[11] Boden WE,Probstfield JL,Anderson T,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med,2011,365(24): 2255-2267.

[12] Sahebkar A,Reiner Z,Simental-Mendia LE,et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials[J]. Metabolism,2016,65(11):1664-1678.

[13] Ooi EM,Watts GF,Chan DC,et al. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus[J]. Arterioscler Thromb Vasc Biol,2015,35(12):2686-2693.

[14] Roeseler E,Julius U,Heigl F,et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization[J]. Arterioscler Thromb Vasc Biol,2016,36(9):2019-2027.

[15] Jaeger BR,Richter Y,Nagel D,et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipo- protein(a) levels and prevent major adverse coronary events[J]. Nat Clin Pract Cardiovasc Med,2009,6(3):229-239.

[16] Khan TZ,Hsu LY,Arai AE,et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial[J]. Eur Heart J,2017,38(20):1561-1569.

[17] Leebmann J,Roeseler E,Julius U,et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy,lipoprotein(a)-hyperlipoproteinemia,and progressive cardiovascular disease: prospective observational multicenter study[J]. Circulation,2013,128(24):2567-2576.

[18] Jaeger BR,Richter Y,Nagel D,et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events[J]. Nat Clin Pract Cardiovasc Med,2009,6(3): 229-239.

[19] Schettler VJ,Neumann CL,Peter C,et al. First data from the German Lipoprotein Apheresis Registry (GLAR)[J]. Atheroscler Suppl,2015 May 18:41-44.

[20] Stefanutti C,Vivenzio A,di Giacomo S,et al. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care[J]. Transfus Apher Sci,2010 Feb 42(1):21-26.

[21] Bohl S,Kassner U,Eckardt R,et al. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging[J].Ther Apher Dial,2009 Apr, 13(2): 129-137.

[22] Raal FJ,Santos RD,Blom DJ,et al. Mipomersen,an apolipoprotein B synthesis inhibitor,for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia:a randomised,double-blind,placebo-controlled trial[J]. Lancet,2010 Mar 375(9719):998-1006.

[23] Stein EA,Dufour R,Gagne C,et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized,double-blind,placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease[J].Circulation,2012 Nov 6 126(19): 2283-2292.

[24] Cuchel M,Meagher EA,du Toit Theron H,et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm,open-label,phase 3 study[J]. Lancet. 2013 Jan 5 381(9860):40-46.

[25] Langsted A,Nordestgaard BG,Benn M,et al. PCSK9 R46L loss-of-function mutation reduces lipoprotein(a),LDL cholesterol,and risk of aortic valve stenosis[J]. J Clin Endocrinol Metab. 2016 Sep 101(9):3281-3287.

[26] Gaudet D,Watts GF,Robinson JG,et al. Effect of alirocumab on lipoprotein(a) over 2:1.5 years (from the Phase 3 ODYSSEY program)[J]. Am J Cardiol,2017,119(1):40-46.

[27] Romagnuolo R,Scipione CA,Boffa MB,et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor[J]. J Biol Chem,2015 May 1 290(18):11649-11662.

[28] Raal FJ,Giugliano RP,Sabatine MS,et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[J]. J Lipid Res,2016 Jun, 57(6):1086-1096.

[29] Lambert G,Thedrez A,Croyal M,et al. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies[J]. Clin Sci (Lond),2017,131(4):261-268.

[30] Ray KK,Landmesser U,Leiter LA,et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med,2017,376(15): 1430-1440.

[31] Tsimikas S,Viney NJ,Hughes SG,et al. Antisense therapy targeting apolipo- protein(a): a randomised,double-blind,placebo-controlled Phase 1 study[J]. Lancet,2015,386(1002):1472-1483.

[32] Viney NJ,van Capelleveen JC,Geary RS,et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised,double-blind,placebo-controlled,dose-ranging trials[J]. Lancet,2016,388(10057):2239-2253.

[33] Langsted A,Nordestgaard BG. Antisense oligonucleotides targeting lipoprotein(a)[J]. Curr Atheroscler Rep,2019,21(8):30.

[34] Kamstrup PR,Tybjaerg-Hansen A,Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population[J]. J Am Coll Cardiol,2014,63(5): 470-477.

[35] Capoulade R,Chan KL,Yeang C,et al. Oxidized phospholipids,lipoprotein(a),and progression of calcific aortic valve stenosis[J]. J Am Coll Cardiol,2015,66(11): 1236-1246.

[36] Kostner GM,Avogaro P,Cazzolato G,et al. Lipoprotein Lp(a) and the risk for myocardial infarction[J]. Atherosclerosis,1981,38(1-2):51-61.

[37] Erqou S,Kaptoge S,Perry PL,et al. Lipoprotein(a) concentration and the risk of coronary heart disease,stroke,and nonvascular mortality[J]. JAMA,2009,302(4):412-423.

[38] Anderson TJ,Gregoire J,Pearson GJ,et al. 2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult[J]. Can J Cardiol,2016,32(11):1263-1282.

[39]汤月霞,吴宗贵.脂蛋白a用于预测心血管疾病的争议[J]. 心血管病学进展,2019,40(8):1158-1161.

相似文献/References:

[1]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
　Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]

备注/Memo

备注/Memo:
通信作者：吴娜琼，E-mail: fuwainaqiongwu@163.com 收稿日期：2020-02-29
更新日期/Last Update: 2021-07-01